All In Biotech

Drug Trial Radar · NCT06990984

A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

A Phase 2a Partially Randomized, Placebo-controlled, Sequential Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jun 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Thiogenesis Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate oral TTI-0102 to evaluate its pharmacokinetics, safety, and preliminary efficacy in patients with Leigh syndrome spectrum, in three sequences. First sequence will be placebo-controlled and include 12 adolescents and adults weighing more than 40 kg. Second sequence will be open-label and include 3 adults and 3 children weighing 25-40 kg. Third sequence will also be open-label and will include 3 children weighing 20-25 kg. The main questions clinical trial aims to answer are: * Characterize the relationship between TTI-0102 drug levels by measuring 1. cysteamine pharmacokinetic (PK) parameters 2. pharmacodynamic (PD) efficacy measures * Generate a population PK model and determine dose level for later dosing groups * collect data to inform the design of a subsequent phase 2b/3 study of TTI-0102 in this patient population Participants will be asked to: * Take the study drug twice daily for 12 weeks * Visit the clinic for checkups and testing 7 times in total: once prior to study drug dosing, then 5 times over the 12-week treatment period and one more time a month after the last study drug dose.

Conditions

  • Leigh Syndrome

Interventions

  • TTI-0102: cysteamine-pantetheine disulfideDrug

    TTI-0102: cysteamine-pantetheine disulfide, powder for dissolution in water for oral administration

  • D-MannitolDrug

    D-Mannitol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK: plasma cysteamine (Tmax)Time frame: Baseline (Day 1) to end of treatment (Day 84)
  2. PK: plasma cysteamine (Cmax)Time frame: Baseline (Day 1) to end of treatment (Day 84)
  3. PK: plasma cysteamine (Cmin)Time frame: Baseline (Day 1) to end of treatment (Day 84)
  4. PK: plasma cysteamine (PK curve)Time frame: Baseline (Day 1) to end of treatment (Day 84)
  5. PK: plasma cysteamine (AUC)Time frame: Baseline (Day 1) to end of treatment (Day 84)
  6. PD: plasma glutathioneTime frame: Baseline (Day 1) to end of treatment (Day 84)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.